What can we learn from various breast cancer trials?
A look at the sheer breadth and depth of bispecific approaches from a myriad of different biotechs
What are Gritstone up to behind the scenes and where are they headed in the near-term?
A look at some hidden gems in the ASCO program and what it all means in terms of the science.
Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!
What's under the hood with a personalised cancer vaccine? Quite a lot it seems!
Science drives oncology new product development and the AACR special conferences are always a good place…
How early evolutionary changes in cancer can impact hot/cold regions and patient outcomes
Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20
Can we learn from what a patient's tumour is telling us in terms of what the immune system is responding to in order to target it therapeutically?
CAR T cell therapy for solid tumors is the cancer new product development equivalent of the quest for the "Holy Grail."
Highlights from SITC 2019 including small cap biotechs with novel or innovative approaches to consider
Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?
Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?
Gritstone have evolved from start-up biotech to clinical stage oncology company. We catch up with them and discuss their latest progress.
Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott
A look a progress on NeoVax in GBM, RNA vaccines and even a novel CAR T cell therapy with a difference.
Achilles Therapeutics is an emerging biotech in the cell therapy space that is based on truncal neoantigens
What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...
A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.
Interview with Prof Kees Melief, CSO ISA Immune System Activation Pharmaceuticals
A look at Ugur Sahin's BioNTech and personalized mRNA vaccines
Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?
Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...
A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?
Update on Neon Tx as they move into commercial new product development with their neoantigen platform.
Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).
Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...
This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.
A primer on neoantigens and their importance in cancer research
How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!
We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...